

HR 4709

Ensuring Patient Access and Effective Drug Enforcement Act of 2014

Congress: 113 (2013–2015, Ended)

Chamber: House

Policy Area: Crime and Law Enforcement

Introduced: May 21, 2014

Current Status: Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and

Latest Action: Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (Jul 30, 2014)

Official Text: <https://www.congress.gov/bill/113th-congress/house-bill/4709>

Sponsor

Name: Rep. Marino, Tom [R-PA-10]

Party: Republican • **State:** PA • **Chamber:** House

Cosponsors (12 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Blackburn, Marsha [R-TN-7]	R · TN		May 21, 2014
Rep. Chu, Judy [D-CA-27]	D · CA		May 21, 2014
Rep. Welch, Peter [D-VT-At Large]	D · VT		May 21, 2014
Rep. Sensenbrenner, F. James, Jr. [R-WI-5]	R · WI		Jul 11, 2014
Rep. Collins, Doug [R-GA-9]	R · GA		Jul 15, 2014
Rep. Griffin, Tim [R-AR-2]	R · AR		Jul 15, 2014
Rep. Holding, George [R-NC-13]	R · NC		Jul 15, 2014
Rep. Johnson, Bill [R-OH-6]	R · OH		Jul 16, 2014
Rep. Gardner, Cory [R-CO-4]	R · CO		Jul 22, 2014
Rep. Smith, Lamar [R-TX-21]	R · TX		Jul 22, 2014
Rep. Amodei, Mark E. [R-NV-2]	R · NV		Jul 23, 2014
Rep. Latta, Robert E. [R-OH-5]	R · OH		Jul 23, 2014

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	May 23, 2014
Health, Education, Labor, and Pensions Committee	Senate	Referred To	Jul 30, 2014
Judiciary Committee	House	Referred to	Jul 21, 2014

Subjects & Policy Tags

Policy Area:

Crime and Law Enforcement

Related Bills

Bill	Relationship	Last Action
113 S 2862	Related bill	Sep 18, 2014: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
113 HR 4069	Related bill	Apr 7, 2014: Subcommittee Hearings Held.

Summary (as of Jul 29, 2014)

Ensuring Patient Access and Effective Drug Enforcement Act of 2014 - Amends the Controlled Substances Act to define: (1) "factors as may be relevant to and consistent with the public health and safety," for purposes of the Attorney General's determination of whether registering an applicant to manufacture or distribute a controlled substance in schedule I or II is in the public interest, as factors that are relevant to and consistent with the findings of such Act; and (2) "imminent danger to the public health or safety," for purposes of the suspension of such a registration, to mean that in the absence of an immediate suspension order, controlled substances will continue to be intentionally diverted outside of legitimate distribution channels or distributed or dispensed outside the usual course of professional practices or in a manner that poses a present or foreseeable risk of serious adverse health consequences or death.

Requires an order to show cause as to why such a registration should not be denied, revoked, or suspended to: (1) contain a statement of the basis for the denial, revocation, or suspension, including specific citations to any laws or regulations alleged to be violated; (2) direct the applicant or registrant to appear before the Attorney General at a specific place and time within 30 days after receipt of the order; and (3) notify the applicant or registrant of the opportunity to submit a corrective action plan on or before such appearance. Requires the Attorney General, upon review of any such plan, to determine whether denial, revocation, or suspension proceedings should be discontinued or deferred for purposes of modifications to such plan. Makes such requirements inapplicable to the issuance of an immediate suspension order.

Directs the Secretary of Health and Human Services (HHS), acting through the Commissioner of Food and Drugs (FDA) and the Director of the Centers for Disease Control and Prevention (CDC), to submit a report identifying: (1) obstacles to legitimate patient access to controlled substances; (2) issues with diversion of controlled substances; and (3) how collaboration between federal, state, local, and tribal law enforcement agencies and the pharmaceutical industry can benefit patients and prevent diversion and abuse of controlled substances.

Actions Timeline

- **Jul 30, 2014:** Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- **Jul 29, 2014:** Reported by the Committee on Energy and Commerce. H. Rept. 113-605, Part I.
- **Jul 29, 2014:** Mr. Pitts moved to suspend the rules and pass the bill, as amended.
- **Jul 29, 2014:** Considered under suspension of the rules. (consideration: CR H7004-7007)
- **Jul 29, 2014:** DEBATE - The House proceeded with forty minutes of debate on H.R. 4709.
- **Jul 29, 2014:** Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.(text: CR H7004-7005)
- **Jul 29, 2014:** On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H7004-7005)
- **Jul 29, 2014:** Motion to reconsider laid on the table Agreed to without objection.
- **Jul 21, 2014:** Referred to the Subcommittee on Crime, Terrorism, Homeland Security, and Investigations.
- **Jun 10, 2014:** Committee Consideration and Mark-up Session Held.
- **Jun 10, 2014:** Ordered to be Reported (Amended) by Voice Vote.
- **Jun 9, 2014:** Committee Consideration and Mark-up Session Held.
- **May 23, 2014:** Referred to the Subcommittee on Health.
- **May 21, 2014:** Introduced in House
- **May 21, 2014:** Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.